American Journal of Cardiovascular Disease Research
ISSN (Print): ISSN Pending ISSN (Online): ISSN Pending Website: Editor-in-chief: Dario Galante
Open Access
Journal Browser
American Journal of Cardiovascular Disease Research. 2024, 9(2), 10-16
DOI: 10.12691/ajcdr-9-2-1
Open AccessArticle

Unlocking the Puzzle: Sex, Hypertension, and SGLT2 Inhibitors - Determinants of LDL-C Target Achievement in Coronary Heart Disease

Desalegn Aychiluhm Abate1, Senbeta Guteta Abdissa2, Zekarias Seifu Ayalew1, Gebeyehu Tessema Azibte1, and Zelalem Belay Ayele1

1Department of Internal Medicine, Addis Ababa University, College of Medicine and Health Sciences, Addis Ababa, Ethiopia

2Division of Cardiology, Department of Internal Medicine, Addis Ababa University, College of Medicine and Health Sciences, Addis Ababa, Ethiopia

Pub. Date: June 06, 2024

Cite this paper:
Desalegn Aychiluhm Abate, Senbeta Guteta Abdissa, Zekarias Seifu Ayalew, Gebeyehu Tessema Azibte and Zelalem Belay Ayele. Unlocking the Puzzle: Sex, Hypertension, and SGLT2 Inhibitors - Determinants of LDL-C Target Achievement in Coronary Heart Disease. American Journal of Cardiovascular Disease Research. 2024; 9(2):10-16. doi: 10.12691/ajcdr-9-2-1


Background: - Globally, cardiovascular diseases (CVD) are the primary cause of death. According to estimates, ischemic heart disease and cerebrovascular illnesses were responsible for 85% of 18 million CVD-related fatalities that occurred globally in 2017. One of the main causative risk factors for atherosclerotic cardiovascular disease is elevated low-density lipoprotein cholesterol (LDL-C). LDL particles can migrate from plasma into the subendothelial region of the artery, where they induce inflammation and lead to the development of atherosclerotic plaques. Thus, LDL-C lowering should be tailored to reach the target objective suggested by guidelines to reduce cardiovascular disease risk. Objective: -Assessment of low-density lipoprotein cholesterol target attainment and associated factors among patients with established coronary heart disease at the cardiology clinic, Tikur Anbessa Specialized Hospital. Methods: - Institutional-based retrospective cross-sectional study design was conducted from August 2023 to October 2023. In this study, among 240 planned participants, 221 participants were extracted, making a chart retrieval rate of 91.7%. Data analysis was done by using SPSS version 26. Multiple regression was applied to identify associated factors. Result: - In this study, about two-thirds of the participants were male, and more than one-third were between the ages of sixty-one and seventy. The level of LDL-C target attainment was 41%. The factors significantly associated with the LDL-C target attainment were male sex (AOR=1.8, 95%CI=1.44, 3.42), hypertension (AOR=0.57, 95%CI=0.31, 0.91), and taking SGLT2 inhibitors (AOR=1.5, 95%CI=1.37, 4.85). Conclusion: The level of LDL-C target attainment was low. Male sex and taking sodium-glucose transporter 2 (SGL2) inhibitors were favorable factors, but hypertension was associated with a low level of LDL target attainment.

low-density lipoprotein cholesterol target coronary heart disease

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


[1]  Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159): 1736-88.
[2]  Hartley A, Marshall DC, Salciccioli JD, Sikkel MB, Maruthappu M, Shalhoub J. Trends in Mortality From Ischemic Heart Disease and Cerebrovascular Disease in Europe: 1980 to 2009. Circulation. 2016; 133(20): 1916-26.
[3]  Cordero A, Bertomeu-Martínez V, Mazón P, Fácila L, Cosín J, Bertomeu-González V, et al. Patients with cardiac disease: Changes observed through last decade in out-patient clinics. World J Cardiol. 2013; 5(8): 288-94.
[4]  Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet. 2020; 395(10226): 795-808.
[5]  Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. Circ Res. 2014; 114(12): 1852-66.
[6]  Danchin N, Almahmeed W, Al-Rasadi K, Azuri J, Berrah A, Cuneo CA, et al. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS). Eur J Prev Cardiol. 2018; 25(10): 1087-94.
[7]  [2016 Chinese guideline for the management of dyslipidemia in adults]. Zhonghua Xin Xue Guan Bing Za Zhi. 2016; 44(10): 833-53.
[8]  Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019; 290: 140-205.
[9]  Barrios V, Soronen J, Carter AM, Anastassopoulou A. Lipid management across Europe in the real-world setting: a rapid evidence review. Curr Med Res Opin. 2021; 37(12): 2049-59.
[10]  Mensah GA, Wei GS, Sorlie PD, Fine LJ, Rosenberg Y, Kaufmann PG, et al. Decline in Cardiovascular Mortality: Possible Causes and Implications. Circ Res. 2017; 120(2): 366-80.
[11]  Moran AE, Forouzanfar MH, Roth GA, Mensah GA, Ezzati M, Murray CJ, et al. Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: the Global Burden of Disease 2010 study. Circulation. 2014; 129(14): 1483-92.
[12]  Townsend N, Nichols M, Scarborough P, Rayner M. Cardiovascular disease in Europe--epidemiological update 2015. Eur Heart J. 2015; 36(40): 2696-705.
[13]  Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016; 37(29): 2315-81.
[14]  Gitt AK, Lautsch D, Ferrieres J, Kastelein J, Drexel H, Horack M, et al. Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients. Atherosclerosis. 2016; 255: 200-9.
[15]  Ramjeeth A, Butkow N, Raal FJ, Maholwana-Mokgatlhe M. The evaluation of low-density lipoprotein cholesterol goals achieved in patients with established cardiovascular disease and/or hyperlipidaemia receiving lipid-lowering therapy: the South African Not at Goal study (SA-NAG). Cardiovasc J Afr. 2008; 19(2): 88-94.
[16]  Wambua PM, Khan Z, Kariuki CM, Ogola EN. A Retrospective Study on the Adoption of Lipid Management Guidelines in Post-Myocardial Infarction Patients in a Tertiary Care Centre. Cureus. 2023; 15(7): e41402.
[17]  Şimşek B, İnan D, Çınar T, Cagdas-Yumurtaş A, Ozan-Tanık V, Zeren G, et al. Evaluation of low-density lipoprotein cholesterol target attainment rates according to the 2016 and 2019 European Society Of Cardiology/European Atherosclerosis Society Dyslipidemia Guidelines for secondary prevention in patients with acute myocardial infarction. Revista de investigación clínica. 2021; 73(6): 371-8.
[18]  Bayoumy K, Gaber M, Mani P, Puri R, Donnellan E, Cho L, et al. LDL-C Targets in Secondary Prevention: How Low Should We Go? Current Cardiovascular Risk Reports. 2019; 13(8): 23.
[19]  Chopra I, Kamal KM. Factors associated with therapeutic goal attainment in patients with concomitant hypertension and dyslipidemia. Hospital Practice. 2014; 42(2): 77-88.
[20]  Banach M, Penson PE. Statins and LDL-C in secondary prevention—So much progress, so far to go. JAMA Network Open. 2020; 3(11): e2025675-e.
[21]  Fleg JL, Forman DE, Berra K, Bittner V, Blumenthal JA, Chen MA, et al. Secondary prevention of atherosclerotic cardiovascular disease in older adults: a scientific statement from the American Heart Association. Circulation. 2013; 128(22): 2422-46.
[22]  Yang YS, Yang BR, Kim M-S, Hwang Y, Choi SH. Low-density lipoprotein cholesterol goal attainment rates in high-risk patients with cardiovascular diseases and diabetes mellitus in Korea: a retrospective cohort study. Lipids in health and disease. 2020; 19: 1-13.
[23]  Groenhof TKJ, Kofink D, Bots ML, Nathoe HM, Hoefer IE, Van Solinge WW, et al. Low-density lipoprotein cholesterol target attainment in patients with established cardiovascular disease: analysis of routine care data. JMIR Medical Informatics. 2020; 8(4): e16400.
[24]  Kim JH, Cha J-J, Lim S, An J, Kim M-N, Hong SJ, et al. Target low-density lipoprotein-cholesterol and secondary prevention for patients with acute myocardial infarction: a Korean nationwide cohort study. Journal of Clinical Medicine. 2022; 11(9): 2650.
[25]  Gavina C, Araújo F, Teixeira C, Ruivo JA, Corte-Real AL, Luz-Duarte L, et al. Sex differences in LDL-C control in a primary care population: The PORTRAIT-DYS study. Atherosclerosis. 2023; 384: 117148.
[26]  van der Meer MG, Cramer MJ, van der Graaf Y, Doevendans PA, Nathoe HM, group) Ss. Gender difference in long-term prognosis among patients with cardiovascular disease. European journal of preventive cardiology. 2014; 21(1): 81-9.
[27]  Laufs U, Karmann B, Pittrow D. Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk. Clinical Research in Cardiology. 2016; 105: 783-90.
[28]  Chopra I, Kamal KM. Factors associated with therapeutic goal attainment in patients with concomitant hypertension and dyslipidemia. Hosp Pract (1995). 2014; 42(2): 77-88.
[29]  Blais JE, Yan VKC, Zhao J, Chui CSL, Wong ICK, Siu CW, et al. Low-Density Lipoprotein Cholesterol Treatment Target Achievement in Patients with Myocardial Infarction, Percutaneous Coronary Intervention, or Stroke in Hong Kong. Reviews in Cardiovascular Medicine. 2022; 23(10): 327.
[30]  Sanchez-Garcia A, Simental-Mendia M, Millan-Alanis JM, Simental-Mendia LE. Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: A systematic review and meta-analysis of 48 randomized controlled trials. Pharmacological Research. 2020; 160: 105068.
[31]  Yaribeygi H, Maleki M, Reiner Ž, Jamialahmadi T, Sahebkar A. Mechanistic view on the effects of SGLT2 inhibitors on lipid metabolism in diabetic milieu. Journal of Clinical Medicine. 2022; 11(21): 6544.
[32]  Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/ AACVPR/ AAPA/ ABC/ ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019; 139(25): e1082-e143.